Session » Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III
- 10:30AM-12:30PM
-
Abstract Number: 2023
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
- 10:30AM-12:30PM
-
Abstract Number: 2008
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
- 10:30AM-12:30PM
-
Abstract Number: 2022
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
- 10:30AM-12:30PM
-
Abstract Number: 2014
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
- 10:30AM-12:30PM
-
Abstract Number: 2013
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
- 10:30AM-12:30PM
-
Abstract Number: 2006
Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy
- 10:30AM-12:30PM
-
Abstract Number: 2015
Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy
- 10:30AM-12:30PM
-
Abstract Number: 2005
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
- 10:30AM-12:30PM
-
Abstract Number: 2018
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
- 10:30AM-12:30PM
-
Abstract Number: 2020
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
- 10:30AM-12:30PM
-
Abstract Number: 2017
Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial
- 10:30AM-12:30PM
-
Abstract Number: 2007
Relationship Between Gout Flare Burden and Patient-Reported Outcome Following Allopurinol Initiation
- 10:30AM-12:30PM
-
Abstract Number: 2009
Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
- 10:30AM-12:30PM
-
Abstract Number: 2019
Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies
- 10:30AM-12:30PM
-
Abstract Number: 2012
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
- 10:30AM-12:30PM
-
Abstract Number: 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
- 10:30AM-12:30PM
-
Abstract Number: 2021
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
- 10:30AM-12:30PM
-
Abstract Number: 2010
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
- 10:30AM-12:30PM
-
Abstract Number: 2011
The Relationship Between Anti-drug Antibodies, Infusion Reactions, and Loss of Urate-lowering Response in Patients with Uncontrolled Gout Treated with Pegloticase
- 10:30AM-12:30PM
-
Abstract Number: 2016
Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)